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Abstract
In this review we discuss skeletal adaptations to the demanding situation of pregnancy and 
lactation. Calcium demands are increased during pregnancy and lactation, and this is effectuated 
by a complex series of hormonal changes. The changes in bone structure at the tissue and whole 
bone level observed during pregnancy and lactation appear to largely recover over time. The 
magnitude of the changes observed during lactation may relate to the volume and duration of 
breastfeeding and return to regular menses. Studies examining long-term consequences of 
pregnancy and lactation suggest that there are small, site-specific benefits to bone density, and that 
bone geometry may also be affected. Pregnancy- and lactation-induced osteoporosis (PLO) is a 
rare disease for which the pathophysiological mechanism is as yet incompletely known; here we 
discuss and speculate on the possible roles of genetics, oxytocin, sympathetic tone and bone 
marrow fat. Finally, we discuss fracture healing during pregnancy and lactation and the effects of 
estrogen on this process.
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31. Introduction
Pregnancy and lactation are challenging situations for the mother’s skeletal homeostasis. 
Significant changes in maternal calcium and bone metabolism must occur to fulfill the calcium 
requirements to build the fetal skeleton. These processes are regulated by hormonal changes and 
often lead to physical changes in the mother’s skeleton. In addition, lifestyle factors which have 
an impact on bone health can alter during pregnancy and lactation.  Physical activity may be lower 
than usual in pregnant women, particularly in the third trimester (1), with the most marked deficits 
in the vigorous activities known to be beneficial to bone homeostasis.  In contrast, the 10-15 kg 
weight gain during a healthy pregnancy (2) as a result of both lean and fat mass gains (3) likely 
increases bone and joint loading during everyday movements.  Whilst nutritional requirements are 
moderately increased during pregnancy (4), this appears to be counterbalanced by concurrent 
reductions in energy expenditure from decreased physical activity.  Accordingly, there is little 
change in diet quality and only a small increase in energy intake during pregnancy and early 
lactation (4,5) without substantial alterations in calcium intake. Despite this, the World Health 
Organization (WHO) recommends an extra dietary calcium intake of 200 mg/day for pregnant 
women compared to non-pregnant women (6,7). Here, we review the current knowledge of how 
the female skeleton physiologically adapts to pregnancy and lactation, how fracture healing is 
affected in these situations, and the pathophysiology of pregnancy- and lactation-induced 
osteoporosis (PLO).
2. Physiological adaptation of bone to pregnancy and lactation
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4A. Hormonal changes during pregnancy
During pregnancy and lactation there is an increased need for calcium in the mother to meet 
the fetus’ calcium requirements (8). In humans, this need is met during pregnancy by increased 
intestinal calcium absorption, and during lactation by increased calcium resorption from bone. 
Bone resorption is mediated by parathyroid hormone-related protein (PTHrP). PTHrP is virtually 
absent in the non-pregnant state, and increases from the first trimester of pregnancy until labor, 
after which levels drop drastically within hours unless breastfeeding is initiated (9). During 
pregnancy PTHrP suppresses and replaces parathyroid hormone (PTH), thereby preventing 
secondary and tertiary hyperparathyroidism. The first 34 amino acids of PTHrP display similarity 
to the structure of PTH, and therefore PTHrP is also a ligand for the PTH/PTHrP receptor. 
However, the mid- and terminal regions of PTHrP are distinct, and have additional functions. The 
mid-molecular region stimulates placental calcium transport in the fetus (10), while the COOH 
terminal region may also inhibit osteoclast activity (11), in addition to the more generally known 
indirect activation of osteoclasts by production of receptor activator of nuclear factor-kappaB 
ligand (RANKL) in (pre)osteoblasts and osteocytes (12,13). PTHrP is released from the placenta 
and breasts in reaction to estradiol, placental lactogen and prolactin, although other tissues 
including the parathyroid glands and uterus also contribute (14-16). During pregnancy high 
estradiol levels largely suppress bone resorption in response to increasing PTHrP. In early 
pregnancy, increased intestinal calcium absorption appears to largely satisfy fetal calcium 
demands, whereas higher demands during late pregnancy may additionally increase bone 
resorption, especially in women with calcium deficient diets (17). However, bone loss cannot be 
prevented by calcium supplementation (18).  Estradiol levels drop during lactation. In combination 
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5with PTHrP, this drop then stimulates bone resorption (14,15) in a synergistic way (19). Oxytocin 
also adds to this effect (see below). 
Physiology in pregnant and lactating humans differs from that of rodents (14). In rodents, 
the increase in serum calcium during lactation is not only dependent on increased bone resorption, 
but also on ongoing increased calcium absorption in the gastrointestinal tract mediated by 
increased concentrations of PTH. 
PTH rises during pregnancy in rodents and the subsequent secondary hyperparathyroidism 
causes both augmented intestinal absorption by increased activation of cholecalciferol into 
calcitriol, and resorption of the skeleton (14). This is in contrast to the suppression of PTH by 
increased PTHrP in humans. Besides PTH (rodents) and PTHrP (human), vitamin D metabolites, 
prolactin and placental lactogen are key regulators of calcium metabolism in mammals (14). 
Together they are responsible for increased calcium levels; by increasing bone resorption, 
stimulating intestinal calcium absorption via synthesis of calcitriol, and reducing urinary calcium 
waste. Calcitriol is elevated during pregnancy in both humans and rodents, and while it declines 
during lactation in humans, it remains elevated in rodents and stimulates intestinal calcium 
absorption. Calcitonin is thought to protect the skeleton from excess resorption during lactation, 
although few data exist for the role of calcitonin and FGF23 in this process (14). 
To summarize, as already reviewed beautifully by Kovacs (14,15), increased calcium 
needs during pregnancy are fulfilled by almost doubling intestinal calcium absorption. 
Meanwhile, during lactation, increased PTHrP levels act synergistically with low levels of 
estrogen to increase bone resorption. In rodents, increased intestinal uptake of calcium continues 
during lactation.
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6Mechanisms of pregnancy-induced bone changes are informed by the study of non-
mammalian models. Birds that lay hard-shelled eggs in part fulfill their calcium requirements by 
resorbing calcium from medullary bone present in the marrow cavities of long bones (20). The 
mechanism of medullary bone turnover is identical to bone turnover in mammals. However, the 
process is triggered by a distinct mechanism, particularly well characterized in the seasonally 
reproducing Japanese quail (Coturnix coturnix japonica). Long day length triggers expression of 
thyroid stimulating hormone (TSH) in the pars tuberalis of the pituitary (21). This induces 
expression of the type 2 iodothyronine deiodinase (DIO2) in the mediobasal hypothalamus (22), 
converting thyroxine prohormone (T4) to bioactive 3,5,3'-triiodothyronine (T3). T3 actions on 
gonadotrophin-releasing hormone (GnRH) nerve terminals trigger release of gonadotrophins from 
the pituitary, increasing gonad size and allowing reproduction. During the egg production cycle, 
hypocalcemia in the mother during shell calcification increases PTH levels, indirectly triggering 
bone resorption and providing calcium for eggshell calcification (23). Resorption of medullary 
bone in avian models therefore represents a model of rapid and pregnancy-related bone turnover.
B. Whole-bone changes during pregnancy and lactation  
Pregnancy
The endocrine and associated metabolic changes which occur during pregnancy and 
lactation result in effects on the skeleton at both the microstructural and whole-bone level.  At the 
microstructural level, results of human iliac crest bone biopsies suggest increased bone resorption 
in early pregnancy (8-10 weeks), whereas at term, resorption is normalised and markers of 
increased bone formation have been observed (24). Bone loss through trabecular thinning and 
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7reduced trabecular connectivity in early pregnancy appear to be regained through the addition of 
new trabeculae by late pregnancy (25). At the whole bone level, bone mineral density (BMD) 
assessed by clinical dual-energy X-ray absorptiometry (DXA) has been shown to decrease by up 
to 5% during pregnancy in the lumbar spine (3,5,26-29), with several reports of smaller losses in 
the hip.  Results at other skeletal sites are more inconsistent; these between-study discrepancies 
may be explained in part by differences in calcium intake, although variations in the timing of 
BMD measurement will also contribute. Quantitative computed tomography (QCT, or pQCT for 
peripheral scanners) gives information on cortical and trabecular bone in addition to detailed bone 
geometry.  However, few studies have employed these techniques to examine pregnancy-related 
changes, and results from the few studies available have been inconsistent. QCT/pQCT studies 
have found no change in cortical, trabecular or total BMD at the radius or tibia (30), distal radius 
cortical BMD (31) or lumbar spine trabecular BMD following pregnancy (5), respectively.  In 
contrast, substantial variation in distal radius trabecular BMD changes between individuals were 
observed in one study, with annual losses of up to 21% (median 1.6%), and with individuals with 
lower baseline BMD values experiencing the greatest losses (31). One recent study has examined 
changes in periosteal and endocortical circumferences and bone microstructure using high-
resolution pQCT (HR-pQCT) to characterise the moderate and site-specific bone losses occurring 
during pregnancy in detail.  The authors found deterioration of trabecular microarchitecture and 
evidence of periosteal and endocortical expansion in women aged 30-45 years across pregnancy 
compared to non-pregnant controls (32). 
Lactation
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8Lactation is associated with decreases in bone mass (33-35), particularly at trabecular-rich 
sites such as the spine and hip (33). These rates of bone loss are pronounced, with a mean 4% loss 
of lumbar spine BMD reported after only 3 months of feeding (33-35).  In contrast, these changes 
are smaller or not evident in formula-feeding mothers or non-pregnant, non-lactating women (33-
35). Unfortunately, to our knowledge no studies have used pQCT to examine changes in 
endocortical and periosteal geometry during lactation.  Changes at the microstructural level can 
also be assessed in vivo using high-resolution pQCT (HR-pQCT). Longitudinal studies of 
breastfeeding women observed increases in cortical porosity and decreased cortical thickness, 
BMD and mineralisation of new bone (36,37).  In the same studies, trabecular number and bone 
volume decreased, whilst contrasting findings with regards to trabecular thickness were observed. 
The latter findings could relate to methodological issues, with trabecularisation of cortical bone 
influencing reported values.  
Lactation-related bone losses vary substantially, with 38% of women losing >5% spine 
BMD (38).  Magnitude of bone loss is positively associated with the amount of breast milk 
produced (33).  Furthermore, rates of bone microstructural change were greater during exclusive 
rather than intermittent feeding (36), and increased with the duration of lactation (37,39).  Taken 
together, these results suggest that increased calcium demand associated with exclusive 
breastfeeding, or increased volume or duration of feeding results in greater bone loss. Given the 
modest changes in calcium intake during pregnancy and the high incidence of vitamin D 
insufficiency in both northern and southern latitudes in pregnant women, it could be suggested that 
dietary insufficiency of these nutrients would contribute to bone changes in pregnancy.  However, 
the majority of studies suggest that vitamin D and calcium levels are not related (3,33,40) or only 
weakly associated to bone turnover markers or bone loss during pregnancy and lactation (41), and 
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9calcium supplementation has been shown to have small (18,30) or transient (34) effects on bone 
loss in pregnancy and lactation (42-46) . Other mechanisms must thus explain these observations.
Following lactation, there appears to be full recovery and even improvements in bone mass 
(34,35,47,48), although this appears incomplete in adolescents (49).  There is some suggestion that 
recovery at the trabecular-rich spine is quicker than in other regions.  In addition, return of regular 
menses and use of the progestin-only contraceptive pill were associated with improved bone 
recovery during and after lactation (35,48,49). Lactation-induced changes in bone microstructure 
did not resolve over a longitudinal study with median follow-up period of 3.6 years (36) such that 
cortical porosity was 0.6 SD higher, and mineralisation density and trabecular number 1.3 SD 
lower in lactating women than controls.  We note that this study did not control for postpartum use 
of hormonal birth control which may have influenced results.   Overall, lactation appears to be 
associated with a series of changes in bone at the macro and microstructural level. Changes at the 
microstructural level do not appear to be fully resolved with time, although it is unclear whether 
compensatory changes at the macrostructural level may preserve strength comparable to the 
increase in periosteal diameter in non-pregnant aging elderly with severe bone loss (50).
Pregnancy in Adolescence
Another area of interest is in adolescent mothers, as it has been hypothesised that pregnancy 
during growth may negatively affect bone accrual. A DXA-based study (four cases, twelve 
matched controls) found 9-10% lower total body and hip BMD (51) in late adolescent mothers at 
follow up at 19-21 years of age, although lactation was not controlled for.  A pQCT-based study 
found a 1% decrease in radius cortical BMD and a 4% decrease in total body BMC in new teenage 
mothers (mean age 18 years) (52) although both studies were limited by small numbers of 
participants. However, these studies focused on later adolescent mothers where pregnancy occurs 
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after peak growth, and this limit understanding of the effects of early post-pubertal pregnancies. 
One study which did examine earlier pregnancies found impaired recovery of post-weaning lumbar 
spine and total body BMD in mothers aged 14 and 15 years compared to those aged 16 or 17 years 
(53).  
Long-term Effects of Pregnancy and Lactation
The long-term effects of pregnancy and lactation on bone characteristics in later life have 
also been examined, and overall small, site-specific benefits to BMD have been observed (54). 
Whilst no strong evidence for differences in BMD was observed between paired 
parous/nulliparous twins, in a large cross-sectional study parity was associated with both greater 
lumbar spine BMD and total body BMC than in other female relatives, whilst breastfeeding was 
associated with higher total body BMC and hip BMD (55). No association between gravidity, 
parity and BMD was observed in women aged 40-80, but parity was associated with greater total 
body and femoral neck bone area (56).  Similarly, cumulative duration of lactation was associated 
with increased femoral neck and tibia bone cross sectional area (CSA) in women 16-20 years after 
their final pregnancy (57). Therefore longer-term effects of pregnancy may primarily relate to 
altered size rather than density (56). These associations appear site-specific, as gravidity and parity 
were not associated with vertebral shape or size at age 46 in a Finnish cohort (58).  This may relate 
to the suppression of estrogens (which inhibit periosteal apposition) during lactation, with similar 
expansion of the axial skeleton observed in both eumenorrheic and amenorrheic athletes with 
lower estrogen levels (59).  The long-term effects of adolescent pregnancy are unclear, having 
been associated with higher BMD (60,61) and lower BMD at multiple sites (62).  In terms of long-
term clinical consequences, parity and lactation were not found to be associated with increased 
fracture risk over 16-year follow-up (63).  
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3. Pathophysiology during pregnancy and lactation
As described in part 2, it is known that bone loss during pregnancy and lactation is a result of 
the hormonal changes that are made to fulfill the increased calcium requirements for fetal and 
neonatal development (14,64,65). If intestinal calcium absorption is insufficient to meet calcium 
demands, calcium is mobilized from the maternal skeleton by either osteoclast activity or 
osteocytic osteolysis mechanisms (14,66), which in turn cause a decrease in bone mass. It is not 
yet understood why some mothers exhibit pregnancy- and lactation-associated osteoporosis (PLO) 
and fracture whilst others do not, despite both having low vitamin D and low estrogen status (65). 
Moreover, at pre-clinical levels it has been shown that maximizing calcium and vitamin D 
physiology through calcitriol supplementation is not sufficient to restore specific bone loss during 
pregnancy and lactation (42-44,46). More recently it has been shown that calcium restriction 
during this period has minimal effects on post-weaning bone metabolic changes (45). These studies 
may explain why some clinical trials failed to demonstrate a full prevention of bone loss during 
pregnancy and lactation with calcium supplementation (18,67). Since it has not been demonstrated 
that differences in inactivity levels can explain PLO, and since pathologically raised PTHrP levels 
are rare (16), other factors including genetic polymorphisms, sympathetic nervous system activity, 
secretion of oxytocin, and bone marrow fat may contribute to bone loss and disturbance of 
microarchitecture during pregnancy and lactation (summarized in Figure 1). This may explain 
some of the differences between physiological and pathophysiological bone loss, i.e. PLO. We 
will discuss each of these in the following paragraph.
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A. Genetics
Early reports have indicated that hereditary factors may play a role in PLO. Osteoporotic 
fractures at younger age more often have a genetic cause (68,69), in contrast to osteoporotic 
fractures at older ages which are often due to simple postmenopausal osteoporosis. Remarkably, a 
high prevalence of fractures has been reported in cases of mothers with PLO (70). Other findings 
included lack of recovery of bone density in the mother during years of follow-up after delivery 
and osteopenia in the children when screened at a young age (71). Finally, a series of five index 
cases with PLO patients revealed osteoporosis, as defined by low BMD, in over half of their 
relatives (72).
Multiple cases have been published which describe patients in whom a genetic cause of 
PLO has been identified. Osteogenesis imperfecta is the best-known form of monogenic 
osteoporosis, and indeed, heterozygous COL1A1 or COL1A2 mutations have been found in several 
cases of PLO (73) (74). These autosomal dominant mutations lead to qualitative or quantitative 
defects in the formation of collagen type I (75). Other cases have been attributed to mutations in 
the gene encoding the LRP5 (low-density lipoprotein receptor-related protein 5) cell-surface 
protein receptor, a key player in intracellular signaling pathways including the Wnt pathway (74). 
Simple and compound heterozygous LRP5 mutations have been described in PLO specifically 
(74,76). Osteoporosis may be associated with visual impairments, such as osteoporosis 
pseudoglioma syndrome/familial exudative vitreoretinopathy, in these patients. This is because 
LRP5 has been shown to be essential for the development of blood vessels in the eye (77) as well 
as bone accrual. The underlying genetic mechanisms may be more complex in some patients, as 
illustrated by the report of a patient with a heterozygous LRP5 mutation together with homozygous 
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polymorphisms in the MTHFR gene encoding methylenetetrahydrofolate reductase, an enzyme 
involved in homocysteine metabolism (78). Intriguingly, osteoporosis did not cosegregate in this 
patient’s family with the LRP5 mutation, the homozygous MTHFR polymorphism, or even the 
combination of the two, implicating additional genetic or non-genetic factors in PLO.
Consideration of a genetic cause for PLO is recommended for patients with a family history 
of osteoporosis and fragility fractures, or a severe phenotype such as a history of fractures before 
pregnancy and severely reduced BMD (Z-score < -2.0 SD). This is especially critical in cases in 
which BMD does not recover in the months after pregnancy and/or weaning (79). Screening for 
an underlying monogenetic bone disorder has been further proposed in patients in whom PLO 
occurs together with one of the following features: joint hypermobility and blue sclerae (indicative 
of osteogenesis imperfecta), congenital blindness, or severely reduced vision (as associated with 
osteoporosis pseudoglioma syndrome). Nowadays, genetic diagnostics are often offered in multi-
gene test panels labeled “osteogenesis imperfecta and related conditions” which may include 
additional variants derived from familial osteoporosis, osteogenesis imperfecta, and genome-wide 
association studies, studies (80-82). The indication for genetic testing should be seriously 
considered, because a diagnosis has significant implications for the patient as well as their 
relatives. Similar to the systematic genetic studies performed for BMD and fractures in general, 
there is a need for genome-wide association studies for PLO (83-86).
B. Oxytocin
Plasma levels of oxytocin peak during late pregnancy and lactation. These periods coincide 
with rapid fetal skeletogenesis and neonatal bone modelling; both processes that require a high 
intake of calcium ions for mineralization, which is delivered by the mother (87). Oxytocin 
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originated as a highly conserved nanopeptide for electrolytic homeostasis in primitive vertebrates 
over 400 million years ago (88). Although it is well known that oxytocin facilitates parturition, 
this hormone is not indispensable for this function (89). In fact, oxytocin knock-out mice (OT-/-) 
can give birth normally but are unable to feed their pups because of the lack of milk ejection reflex. 
This defect is completely reversible by peripheral injection of oxytocin, suggesting that its primary 
role in mammalian lactation is mediated by a peripheral action rather than a central mechanism 
(89). Conversely, the regulation of maternal and sexual behavior, social memory, and penile 
erection and ejaculation in males, are mediated by a central action of oxytocin (90-93). 
In addition to its action on social behavior, milk ejection, and uterine contraction, receptors 
for oxytocin are expressed on osteoblasts, osteoclasts, and their precursors (94,95). Furthermore, 
bone marrow osteoblasts synthesize oxytocin, suggesting the existence of an oxytocin/oxytocin 
receptor system in the bone milieu regulated by autocrine and paracrine interactions (95,96). 
Oxytocin stimulates osteoblast differentiation (97), and OT-/- mice as well as mice lacking the 
oxytocin receptor (OTR-/-) display reduced bone mass, mainly due to a bone-forming defect (95). 
Systemic injections of oxytocin into wild-type rodents increase bone mass and improve 
osseointegration of titanium implants (98) (99). At the same time, oxytocin stimulates 
differentiation of pre-osteoclastas (Figure 1) by increasing the ratio of RANKL and 
osteoprotegerin (OPG), while inhibiting bone resorption by triggering cytosolic Ca2+ release and 
nitric oxide synthesis. More specifically, oxytocin increases the expression of the Ca2+ sensitive 
NOS isoform (eNOS) and triggers a time-dependent increase in the production of nitric oxide, as 
a mechanism to inhibit bone resorption (95). Altogether these results are consistent with the 
hypothesis that oxytocin is responsible for maintaining a high rate of cell activity in bone, 
stimulating the proliferation of both forming and resorbing cells, while at the same time controlling 
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the amount of bone resorbed. The inhibitory effect of oxytocin on mature osteoclasts may serve as 
a checkpoint for bone resorption that would otherwise be unrestricted following stimulation of 
osteoclastogenesis
PTHrP, indispensable for the development of the mammary gland, and pro-resorptive 
during breastfeeding (100), is only partly responsible for the intergenerational calcium transfer. It 
has been suggested that this complex process, fundamental for skeletal morphogenesis, is also 
driven by oxytocin. The anabolic effect of oxytocin may facilitate the restoration of the maternal 
skeleton while its pro-osteoclastogenic action may contribute to the intergenerational transfer of 
calcium. As evidence of this, pregnant OT-/- mice have reduced markers of bone formation, and 
OT-/- pups displayed hypo-mineralized skeletons (101). Furthermore, pregnant wild type mice 
exhibited increased plasma levels of C-telopeptide, a marker of bone resorption, and osteoclast 
cultures obtained from the bone marrow of these mice showed higher numbers of TRAP-positive 
cells than non-pregnant mice (101). Intraperitoneal injections of oxytocin thrice weekly for 
5 weeks in non-pregnant mice, as well as the addition of oxytocin to bone marrow cell cultures 
obtained from control mice, mimicked this pregnancy-induced increase in osteoclastogenesis 
(101). A similar result has been obtained in twelve healthy women with spontaneous vaginal 
deliveries at term. The number and size of osteoclasts generated in vitro from peripheral blood of 
these women were significantly higher than age- matched controls (102).  
Overall, these findings show that the enhanced osteoclast formation can be explained by 
elevated oxytocin levels during late pregnancy (103).  Consistent with this hypothesis, pregnant 
mice lacking oxytocin showed a ∼80% reduction in ex vivo osteoclast formation compared with 
wild type pregnant littermates, suggesting that the osteoclastogenesis triggered in pregnant mice 
is, at least in part, dependent upon an intact oxytocin axis. It is therefore possible that the increase 
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in serum oxytocin levels during pregnancy is responsible for the increase in osteoclast formation 
which tends to mobilize maternal calcium for fetal skeletogenesis to occur. Additionally, 
considering that oxytocin mainly stimulates osteoblastogenesis (95), it has been investigated 
whether osteoblast formation ex vivo was enhanced in pregnant wild type mice, and whether this 
response was reduced in oxytocin-deficiency. As expected, the formation of alkaline phosphatase-
positive colonies (CFU-f) was increased during pregnancy in mice, as mimicked by intraperitoneal 
oxytocin injection, thrice weekly, in non-pregnant mice, indicating that oxytocin might be 
responsible for inducing osteoblast formation (101). The uncoupling of bone remodeling from net 
skeletal loss during lactation has been mainly ascribed to decreased levels of estrogen (100). 
However, estrogen deficiency during menopause causes irreversible bone loss, while PLO is 
mostly reversible in both rodents and humans (104). Nevertheless, maternal bone loss would be 
continuous in the absence of a mechanism that would inhibit excessive osteoclastic resorption. 
Therefore, it has been proposed that oxytocin, which also inhibits resorption by mature osteoclasts 
(95), provides one of these mechanisms for the self-regulation of oxytocin-induced 
osteoclastogenesis and bone loss. Overall, these studies indicate that oxytocin, which is also a 
mammary gland-specific peptide (89), is important for the regulation of intergenerational calcium 
transfer and is possibly also mechanistically involved in PLO in humans.
C. Sympathetic nervous system
Genetically and pharmacologically induced over-activity of the sympathetic nervous system 
(SNS) has been well demonstrated to be deleterious for bone mass and structure (105-108). This 
is explained by an increase in bone resorption through enhanced activating transcription factor 
4(ATF4)/RANKL secretion by osteoblasts (109), in combination with decreased 
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osteoblastogenesis (105). In line with this, a recent randomized clinical trial demonstrated that 
patients treated with β-adrenoreceptor-selective blockers had better bone microarchitecture than 
nonusers (110). It has been demonstrated that SNS activity is important for regulation of pregnancy 
and lactation (111,112), but to our knowledge, the direct contribution of the SNS to PLO has never 
been investigated or reported. 
During pregnancy (113), the increase in neural activity is likely to manifest as an increase in 
the release of neurotransmitters such as norepinephrine (NE) and neuropeptide Y (114,115), 
resulting in an early increase in blood pressure within the first few weeks of conception (116,117). 
Since both neurotransmitters are linked to bone metabolism (118-120) we speculate that they could 
be involved in PLO, although this has not been studied to date. During lactation, levels of both 
NE and serotonin (5-hydroxytryptamine, 5HT) in the anterior cerebral cortex, hippocampus, and 
cerebellum have been shown to increase, particularly from late pregnancy to early postpartum 
period, and continue to increase in the postpartum period (121). This implicates NE and serotonin 
in the regulation of hormone secretion and bone metabolism changes during these periods. The 
increased SNS activity during lactation is magnified during post-partum depression, which occurs 
in 25-35% in pregnant women after delivery (122). Interestingly, a connection between depression, 
bone loss and SNS activity increase has been demonstrated (123). Moreover, modulation of the 
SNS could also control other tissues such as adipose tissue (124) which is well known to be 
associated with bone remodeling levels (125,126). However, as stated, the role of SNS in PLO 
remains highly speculative.
D. Bone marrow fat
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Bone marrow adipocytes appear in the bone marrow directly after birth and continue to expand 
throughout the skeleton during growth. In humans, at the age of 25 years, most of the marrow of 
the long bones is occupied by adipocytes, whereas in the axial skeleton the marrow remains mostly 
hematopoietic. However, bone marrow adipocytes accumulate with aging, and there is a clear 
inverse association between bone marrow adiposity and bone mass, which is accentuated in 
diseases characterized by increased fracture risk such as osteoporosis. This is hypothesised to be 
due to a shift in the lineage allocation of the skeletal stem cell, favoring adipogenesis over 
osteoblastogenesis. However, situations of ‘beneficial’ increased bone marrow adiposity have also 
been described, such as hematopoietic regeneration following radiation or chemotherapy. In this 
situation bone marrow adipocytes are hypothesised to be a source of energy by supplying fatty 
acids to hematopoietic and bone cells (127). 
Studies of bone marrow adiposity during pregnancy and lactation have not been performed in 
humans. In rats, bone marrow adipocytes, as assessed by histomorphometry of the vertebrae, 
decrease both in number and volume during and after pregnancy, in lactating and non-lactating 
mothers, compared to non-pregnant controls (128). The changes in bone marrow adipocytes were 
negatively correlated with changes in bone formation parameters, although the decrease in bone 
marrow adiposity was accompanied by a decrease in bone volume. In mice, bone marrow 
adiposity, as assessed by osmium staining of the tibia, also decreases significantly during lactation 
and this was accompanied by a decrease in trabecular bone volume (129). These two studies show 
that bone marrow adiposity decreases during pregnancy and lactation, and this is accompanied by 
a decrease in bone volume. A possible hypothesis is that the bone marrow adipocytes undergo 
lipolysis to provide fatty acids as an energy source for the increased bone resorption due to the 
increased calcium demands both for fetal skeletal development and for maternal milk production. 
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Interestingly, the disappearance of adipocytes during lactation has also been described in the 
mammary gland of mice (130). Mammary adipocytes were shown to undergo de-differentiation 
during lactation and re-differentiation during weaning. Whether bone marrow adipocytes could 
also undergo this de- and re-differentiation remains to be investigated.
E. PLO profile and treatment
PLO is rare, and its prevalence is unknown. The occurrence of fragility fractures appears 
mostly in the third trimester and lactation period (131), typically presenting in the first pregnancy 
with acute back pain from (multiple) vertebral fragility fractures and subsequently determined low 
BMD. Since premenopausal women rarely undergo DXA scanning, the pre-pregnancy BMD in 
these women is mostly unknown. Bone loss, predominantly from trabecular bone sites, in 
combination with the increased weight bearing and the lordotic posture of pregnancy, is assumed 
to lead to these spontaneous vertebral fractures. Decreased BMD prior to pregnancy in such 
premenopausal women is mostly caused by osteoporosis secondary to anorexia nervosa, endocrine 
diseases (e.g. Cushing’s disease, hyperthyroidism or primary hyperparathyroidism), inflammatory 
diseases (e.g. rheumatoid arthritis or inflammatory bowel diseases) or medication (e.g. 
glucocorticoids or cancer treatments) (15).
Vertebral fractures presenting with back pain should be treated with appropriate pain 
medication and advice on weight bearing and mobility. Quality of life and capacity to work should 
also be taken into account, although long-term prognosis for PLO is good (132). In general, 
pharmacological treatment for low bone mass is not indicated, except calcium and vitamin D 
supplements, since bone mass recovers fully in the year following weaning and the onset of the 
menstrual cycle (3). Several studies have shown that parity and lactation are not associated with 
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increased long-term risk of postmenopausal osteoporosis and fractures, and may even protect 
against hip fractures (133,134). Moreover, PLO typically presents in first pregnancy, with limited 
evidence for increased fracture risk in future pregnancies (17,135). In contrast, Kyvernitakis et al 
have shown that the refracture risk in subsequent pregnancies is 20%, and the refracture rate after 
6 years is 25%, with risk positively related to the number of fractures during the pregnancy (136). 
Therefore, it remains important to counsel women with PLO on the fracture risk associated with 
lactation and further pregnancies. Treatment with anti-osteoporosis medication such as the anti-
resorptive bisphosphonates, the anabolic PTH anaologue teriparatide, and the human monoclonal 
RANKL antibody denosumab has been shown to be effective in increasing BMD, although there 
are no data on fracture outcomes and the reported studies did not include a placebo-treated control 
(17). In addition, the possible fracture reduction following treatment with bisphosphonates that are 
retained in the bone (137) should be weighed against a possible negative effect on skeletal 
development of the fetus in following pregnancies and other pregnancy related complications such 
as low birth weight. Although the limited available evidence in humans has not indicated that 
bisphosphonate treatment causes major congenital anomalies, the number of patients exposed is 
not sufficient to draw any conclusions on the safety profile of these medications (138). Moreover, 
use of teriparatide and denosumab are contraindicated during pregnancy and lactation and should 
therefore be used with caution in patient groups of fertile age. 
F. Fracture healing during pregnancy
Although severe fractures are rather rare during pregnancy, several clinical case reports have 
described fracture healing during pregnancy (139-142). These studies suggest that fracture healing 
is accelerated during pregnancy, based on earlier bone bridging of the fracture callus and reduced 
time until bony union. This appears to be independent from the stage of pregnancy at which the 
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fracture occurred. Accelerated bone regeneration may be due to the positive impact of several 
pregnancy-associated growth factors (such as pregnancy-associated plasma protein-A and 
placental growth factor) on fracture healing, which was demonstrated in experimental studies 
(143,144). Increased estrogen levels may also account for improved bone regeneration, as estrogen 
application was shown to accelerate fracture healing (145). In line with this, several experimental 
studies in rodent models of estrogen-deficiency demonstrated delayed fracture healing. 
Ovariectomised (OVX), estrogen-deficient rats and mice displayed decreased mechanical 
properties and bone formation in the late fracture callus (146-148). The number of osteoclasts was 
significantly increased during callus development (149). This might be explained by the effects of 
estrogen in increasing osteoclast and decreasing osteoblast apoptosis (150-152), and by stimulating 
the recruitment, proliferation and differentiation of skeletal progenitor cells (153,154). Analysis of 
the intermediate phase of endochondral fracture healing in OVX mice further demonstrated a 
decreased cartilaginous callus area (145) and a reduced expression of cartilage markers (155) and 
angiogenic factors (156). Therefore, bone regeneration appears to be disturbed by estrogen-
deficiency both during the middle and late phases of healing, with changes in angiogenesis and the 
formation of the cartilaginous and the bony callus. The molecular mechanisms underlying these 
findings remain unclear. However, as it is known that postmenopausal females display a chronic 
low-grade inflammatory phenotype and the inflammatory response to injury is altered under 
estrogen-deficiency (157-159), estrogen may also modulate the inflammatory response after 
fracture. Indeed, recent studies demonstrated an imbalanced immune response to fracture in OVX 
mice and postmenopausal fracture patients (160,161). In particular, the molecule midkine (Mdk) 
appears to play an important role in this process. Mdk is known to be both a proinflammatory 
cytokine regulated by estrogen (162) and a negative regulator of bone formation (163) and fracture 
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healing (164). Indeed, antibody inhibition of Mdk reduced the negative effects of serum from 
postmenopausal fracture patients on the osteogenic differentiation of human MSCs. Overall, 
accelerated fractured healing during pregnancy might be due to the positive effects of increased 
estrogen levels on bony and cartilaginous callus formation as well as on the inflammatory response 
after fracture. 
Conclusion
Reproduction brings about changes in the endocrine-mediated processes of calcium, 
mineral and bone metabolism. This applies to pregnancy in humans and other mammals, as there 
is a need for building material for the fetal skeleton. Moreover, physical changes occuring in 
pregnant and lactating women such as excessive weight on the lumbar spine region cause 
physiological and pathophysiological changes which are not yet fully elucidated. We have 
discussed the possible contribution of oxytocin, genetics, bone marrow fat and the SNS to 
pathophysiological changes such as PLO. Finally, fracture healing appears to be improved during 
pregnancy, and this is possibly due to the positive effects of estrogen on bone regeneration. 
Glossary of abbreviations
ATF4: Activating Transcription Factor 4
COL1A1: COLlagen Alpha1
DIO2: type 2 iodothyronine deiodinase 
FGF23: fibroblast Growth Factor 23
GnRH: Gonadotrophin-Releasing Hormone
5HT: 5-HydroxyTryptamine or serotonin
LRP5: Low-density Llipoprotein Receptor-related Protein 5 
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Mdk: Midkine, also known as neurite growth-promoting factor 2 (NEGF2)
MTHFR: Methylene TetraHydroFolate Reductase
NE: norepinephrine, also called noradrenaline
OPG: Osteoprotegerin, also known as osteoclastogenesis inhibitory factor
OT: OxyTocin
PRL: Prolactin, also known as luteotropin 
PTH: ParaThyroid Hormone 
PTHrP: ParaThyroid Hormone-related Protein
RANK: Receptor Activator of Nuclear factor κ B
RANKL:  RANK-Ligand
TRAP: Tartrate-Resistant Acid Phosphatase
TSH: Thyroid Stimulating Hormone, also known as thyrotropin
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Figure legend
Figure 1. Proposed model for the control of osteoclastogenesis and resorptive function of 
osteoclast (OCs) during adaptations of the skeleton to the demanding situations of pregnancy and 
lactation. Parathyroid hormone-related protein (PTHrP), synthesized in the placenta, breast tissue, 
parathyroid glands and the uterus, is the main actor of increased bone resorption. The increased 
production of oxytocin (OT) from the posterior pituitary stimulates osteoclastogenesis by acting 
on the osteoclast precursor (preOCs). The over-activity of the sympathetic nervous system (SNS), 
which increases release of neurotransmitters such as norepinephrine, stimulates bone resorption 
through an enhanced RANKL secretion by osteoblasts (OBs). In the bone marrow adipose tissue 
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(BMAT), adipocytes undergo lipolysis to provide fatty acids as an energy source for the increased 
bone resorption.
Page 33 of 34 Accepted Manuscript published as EC-20-0055.R1. Accepted for publication: 12-May-2020
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 05/14/2020 01:02:13PM
via Manchester Metropolitan Univ
 Figure 1. Proposed model for the control of osteoclastogenesis and resorptive function of osteoclast (OCs) 
during adaptations of the skeleton to the demanding situations of pregnancy and lactation. Parathyroid 
hormone-related protein (PTHrP), synthesized in the placenta, breast tissue, parathyroid glands and the 
uterus, is the main actor of increased bone resorption. The increased production of oxytocin (OT) from the 
posterior pituitary stimulates osteoclastogenesis by acting on the osteoclast precursor (preOCs). The over-
activity of the sympathetic nervous system (SNS), which increases release of neurotransmitters such as 
norepinephrine, stimulates bone resorption through an enhanced RANKL secretion by osteoblasts (OBs). In 
the bone marrow adipose tissue (BMAT), adipocytes undergo lipolysis to provide fatty acids as an energy 
source for the increased bone resorption. 
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